EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years



Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years



Gastroenterology 131(6): 1743-1751



Background & Aims: Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued. We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for LIP to 240 weeks. Methods: HBeAg-negative patients were treated double blind with placebo or adefovir dipivoxil 10 mg once daily for 48 weeks, followed by adefovir dipivoxil from week 49 to 96. At week 97, 125 patients enrolled in a 144-week, open-label phase. Patients received adefovir dipivoxil for up to 192 or 240 weeks. Results: Serum hepatitis B virus (HBV) DNA levels were less than 1000 copies per milliliter in 67% of patients, and alanine aminotransferase (ALT) levels normalized in 69% after 240 weeks. After 192 or 240 weeks of treatment, over 83% of patients had improvement in necroinflammation, and over 73% had improvement in fibrosis. Ishak fibrosis scores improved compared with baseline in 35%, 55%, and 71% of patients after 48, 192, and 240 weeks of adefovir dipivoxil, respectively. After 240 weeks, the cumulative probability of HBV polymerase mutations was 29%, but the cumulative probability of mutations with virologic resistance was 20% and of mutations, virologic resistance, and ALT elevations was 11%. Slight elevations in creatinine were confirmed in 4 (3%) patients. Conclusions: Treatment with adefovir dipivoxil for up to 240 weeks was well tolerated and produced significant, increasing improvement in hepatic fibrosis, durable suppression of HBV replication, normalization of liver enzymes, and delayed development of resistance.

(PDF emailed within 0-6 h: $19.90)

Accession: 012989849

Download citation: RISBibTeXText

PMID: 16649389

DOI: 10.1053/j.gastro.2006.09.020



Related references

Long-Term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. Yearbook of Pediatrics 2007: 156-157, 2007

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New England Journal of Medicine 352(26): 2673-2681, 2005

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitits B. Yearbook of Gastroenterology 2006: 277-278, 2006

Long-term adefovir dipivoxil in HBeAg negative chronic hepatitis results in significant virological, biochemical and histological improvement. Hepatology 38(4 Suppl 1): 273A, October, 2003

Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B. Gastroenterologia Y Hepatologia 34(2): 69-74, 2011

Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. Journal of Viral Hepatitis 20 Suppl 1: 40-45, 2013

Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 22(3): 181-184, 2014

Lack of ethnic differences in response to adefovir dipivoxil therapy in HBeAg+ and HBeAg- patients with chronic hepatitis B. Hepatology 38(4 Suppl 1): 714A-715A, October, 2003

The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences 28(4 Suppl): 1493-1497, 2015

Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver International 31(10): 1525-1532, 2012

Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients. Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi 24(1): 39-41, 2010

Loss of serum HBV DNA and HBeAg and seroconversion following short-term adefovir dipivoxil therapy in chronic hepatitis B Two placebo-controlled phase II studies. Hepatology 28(4 PART 2): 317A, 1998

The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment. Acp Journal Club 144(1): 4-4, 2006

Resistance surveillance of HBeAg- chronic hepatitis B patients treated for two years with adefovir dipivoxil. Journal of Hepatology 38(Supplement 2): 182, April, 2003

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver International 32(1): 137-146, 2012